The upcoming oral presentation at the European Society for Medical Oncology (ESMO) Congress focuses on the single-agent activity of invikafusp alfa, a bispecific dual T-cell agonist. By targeting specific Vβ6/Vβ10 T-cell subsets, the drug aims to overcome resistance in patients with advanced solid tumors, particularly those with high tumor mutational burden (TMB-H). Data will be presented on October 23, 2026, by Dr. Elena Garralda, building on earlier findings that suggested selective T-cell activation could serve as a potent monotherapy where traditional immune checkpoint blockade fails.

Dr. Eric Rubin joins the team to oversee the transition of invikafusp alfa into more rigorous clinical evaluation. During his 16-year tenure at Merck, Rubin spearheaded the development of pembrolizumab, establishing the drug as a foundational immuno-oncology treatment. His appointment signals a strategic shift for Marengo as it moves beyond initial safety trials toward defining the specific biomarker-selected cohorts most likely to benefit from its proprietary STAR platform. The company intends to use these results to determine if their T-cell targeting approach can eventually function as a combination backbone for earlier-line cancer treatments.